UNSPSC 51333002: Milipertine

This classification denotes a dopamine antagonist with the molecular formula C24H31N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WX1V67H28T, chemically known as 5,6-dimethoxy-3-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-2-methylindole but generally known as milipertine, which bears US NIH Compound Identifier 32345. European Medicines Agency schedules Milipertine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08964MIG. The term MILIPERTINE is an International Non-Proprietary Name.

UNSPSC 51333002 Milipertine, a Commodity code, encompasses pharmaceutical products and delivery systems that state and local health agencies procure to support community health and emergency response initiatives. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals with over-the-counter products, and therapeutic pharmacy program support through direct-to-manufacturer relationships. The issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Procurement vehicles range from competitive sealed bids for discrete annual supply contracts to requests for information and formal RFPs establishing multi-vendor supply frameworks.

Activity appears concentrated in Florida and Minnesota, with involvement from Texas through its Health and Human Services Commission. Representative recent solicitations include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023), requiring quarterly deliveries and electronic bidding through the county's e-Procurement Portal; the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026), administered by the Minnesota Department of Administration and extending to participating jurisdictions including Oregon, with awards effective July 1, 2026; and the Texas Health and Human Services Commission's Request for Information (HHS0017013, posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Cooperative purchasing vehicles appear to offer broader geographic reach and multi-year contract terms, while direct county procurements tend toward fixed-term agreements with renewal options and stricter delivery and compliance schedules.